Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Trial Profile

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itacitinib (Primary) ; Parsaclisib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Acronyms CITADEL-101
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 01 Jun 2022 The protocol was amended to allow patients to receive Parsaclisib 5 mg QD, 30 mg QD, 45 mg QD, Parsaclisib 20 mg + itacitinib (INCB039110) 300 mg, Parsaclisib 30 mg + itacitinib (INCB039110) 300 mg, Parsaclisib 20 mg QD + R-ICE (placebo), and Parsaclisib 15 mg QD + R-ICE (placebo), according to ClinicalTrials.gov record. Accordingly, the number of arms were increased from 3 to 10.
    • 01 Jun 2022 The primary endpoint Safety and tolerability assessed by summary of Adverse Events (AEs), clinical lab assessments, physical exam results, and 12-lead ECGs for Parsaclisib as monotherapy and as a combination therapy was changed to Number of Participants With Treatment-emergent Adverse Events (TEAEs), according to ClinicalTrials.gov record.
    • 03 May 2021 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top